BioSpace News Archive

Bristol Myers Squibb announced that its previously announced tender offer to acquire all of the outstanding shares of RayzeBio, Inc. common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion, expired at one minute after 11:59 p.m., Eastern Time, on February 22, 2024.

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen Healthcare Conference on Tuesday, March 5, 2024.

Actinium Pharmaceuticals, Inc., a leader in the development of targeted radiotherapies, highlighted results from three poster presentations at the 2024 Tandem Meetings | Transplantation & Cellular Therapy Meetings of ASTCT® being held in San Antonio, Texas.

Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech) announced today the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended expansion of the CARVYKTI® label to include adult patients with relapsed and refractory multiple myeloma, who have received at least one prior therapy, including an immunomodulatory agent and a proteasome inhibitor, have demonstrated disease progression on the last therapy, and are refractory to lenalidomide.

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) announced today that the company will present findings from four studies evaluating apraglutide in adults with short bowel syndrome with intestinal failure (SBS-IF), a condition in which they are dependent on parenteral support, during the American Society for Parenteral and Enteral Nutrition (ASPEN) 2024 Nutrition Science & Practice Conference.